New Onset clinical trials at UCSF

1 research study open to eligible people

Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
open to eligible people ages 9-21
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.
San Francisco, California and other locations

Our lead scientists for New Onset research studies include Stephen Gitelman.

Last updated: May 14, 2026

Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes